Screening in a spirit haunted world

Drug Discov Today. 2006 Jul;11(13-14):607-15. doi: 10.1016/j.drudis.2006.05.014.


High-throughput screening (HTS) campaigns can be dominated by hits that ultimately turn out to be non-drug-like. These "nuisance" compounds often behave strangely, with steep dose-response curves, absence of clear structure-activity relationships, and high sensitivity to assay conditions. Several mechanisms contribute to these artifacts, including chemically reactive molecules, those that absorb light in assays and those that affect redox conditions. One of the most common mechanisms behind artifactual inhibition is discussed in this review: at micromolar concentrations organic molecules can aggregate to form particles in aqueous buffers, and these aggregates can sequester and thereby inhibit protein targets. Aggregation-based inhibition is baffling from a chemical perspective, but viewed biophysically such behavior is expected. The range of molecules that behave this way, their rapid detection in a screening environment and their possible biological implications will be considered here.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Artifacts*
  • Biological Assay / methods
  • Chymotrypsin / antagonists & inhibitors
  • Chymotrypsin / chemistry
  • Chymotrypsin / metabolism
  • Colloids
  • Drug Design*
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / pharmacology
  • Models, Chemical
  • Molecular Conformation
  • Molecular Structure
  • Protein Conformation
  • beta-Lactamase Inhibitors
  • beta-Lactamases / chemistry
  • beta-Lactamases / metabolism


  • Colloids
  • Enzyme Inhibitors
  • beta-Lactamase Inhibitors
  • Chymotrypsin
  • beta-Lactamases